According to CNBC, Elliott Management made an all-cash deal for Athenahealth on Monday morning. Elliott’s bid is for $160 a share—a 27 percent premium to the Massachusetts-based healthcare technology company’s Friday afternoon price.

For outpatient surgery, those with lower health literacy experienced poorer recovery and decreased quality of life, according to an April 25 study published in JAMA Surgery.

Researchers at the University of Texas at Arlington have developed a flexible biodegradable hydrogel capable of printing human tissues. The team published its findings March 18 in ACS Applied Materials and Interfaces.

More than one-third of readmissions within seven days of discharge—36 percent—are preventable, according to research published May 1 in the Annals of Internal Medicine.

One of Massachusetts’ largest health insurers, Harvard Pilgrim, has been discussing a merger with the state’s dominant healthcare provider, Partners HealthCare, in a move that could dramatically alter the increasingly consolidated market in and around Boston.

Former University of Pittsburgh Medical Center (UPMC) radiologist Marios D. Papachristou waived indictment and pleaded guilty May 3 to federal charges of healthcare fraud and illegally distributing controlled substances to non-patients, the U.S. Department of Justice has announced.

iSchemaView announced this week it has received FDA clearance for RAPID CTA, the most recent addition to the company’s neuroimaging platform.

A paclitaxel-coated balloon demonstrated significantly higher primary patency rates at 12 months and lower odds of reintervention when compared to uncoated balloon angioplasty for femoropopliteal lesions, according to the first randomized, one-year study of the device.

Big changes are everywhere in today’s business world, according to a new study published in the Journal of the American College of Radiology. So what, exactly, does this mean for radiology?

A team of U.S. researchers utilized brain imaging to find problems in white matter connectivity in infants with the genetic neurodevelopment disorder Fragile X syndrome (FXS), pointing to the areas as possible targets for intervention.